Oncology Times - Melflufen
- Leena Chhun
- 14 hours ago
- 1 min read
In a recent article published in Oncology Times, Dr. Tony Blau was interviewed along with Dr. Paul Richardson, Dr. Yvonne Efebera, and Dr. Heinz Ludwig about Melflufen (Melphalan Flufenamide).
The FDA withdrew approval for Melflufen's use in relapse and refractory Multiple Myeloma in the U.S in October 2021. In contrast, the EMA (European Medicines Agency) approved the use of Melflufen in the E.U. in August 2022.
To read more about what Dr. Blau, Dr. Richardson, Dr. Efebera, and Dr. Ludwig had to say regarding Melflufen, please read the free article here or download the attachment.
